Showing results (131-140 of 281) with videos related to

Sort By:
Pageof 29
The American Journal of Cardiology|July 12, 2007
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialDavid C Goff, Hertzel C Gerstein, Henry N Ginsberg, et al.
Hypertension (Dallas, Tex. : 1979)|September 27, 2014
Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Paul Muntner, Barry R Davis, William C Cushman, et al.
Cardiovascular Diabetology|March 10, 2023
General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trialEdward Franek, Prem Pais, Jan Basile, et al.
American Heart Journal|October 11, 2011
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndromeWilliam B White, George L Bakris, Richard M Bergenstal, et al.
American Health & Drug Benefits|March 9, 2022
Effects of the Medicare Part D Comprehensive Medication Review on Racial and Ethnic Disparities in Medication AdherenceXiaobei Dong, Chi Chun Steve Tsang, Shirong Zhao, et al.
The Journal of Clinical Endocrinology and Metabolism|February 4, 2021
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trialMatthew C Riddle, Hertzel C Gerstein, Denis Xavier, et al.
Circulation|November 13, 2008
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trialBarry R Davis, John B Kostis, Lara M Simpson, et al.
The American Journal of Medicine|December 17, 2016
Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHATSripal Bangalore, Barry R Davis, William C Cushman, et al.
Kidney International|December 15, 2011
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patientsFaramarz Ismail-Beigi, Timothy E Craven, Patrick J O'Connor, et al.
Hypertension (Dallas, Tex. : 1979)|August 3, 2016
Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor AlogliptinWilliam B White, Craig A Wilson, George L Bakris, et al.
Pageof 29